Insilico Medicine has initiated a global clinical trial for ISM3412, an AI-designed MAT2A inhibitor, in patients with advanced solid tumours. The Phase 1 trial will assess the drug's safety, tolerability, and preliminary efficacy, as well as determine the optimal dose for future studies. Participants will receive ISM3412 orally once daily. The trial includes dose escalation and optimisation phases. The first patient has been dosed at the Cancer Hospital Chinese Academy of Medical Sciences.
ISM3412, created using Insilico's Chemistry42 platform, targets cancers with MTAP deletion, a common genetic alteration in tumours like lung and pancreatic cancer. By inhibiting MAT2A, ISM3412 reduces S-adenosylmethionine (SAM) levels, crucial for cell proliferation. Preclinical studies showed promising efficacy and safety. Insilico has advanced six pipelines to the clinical stage since 2021.
